(Q37803220)

23 August 2017

title

Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder (English)

1 reference

23 August 2017

1 reference

1 reference

William V Bobo

1

1 reference

23 August 2017

Richard C Shelton

series ordinal

2

1 reference

23 August 2017

publication date

1 November 2010

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

23 August 2017

published in

1 reference

23 August 2017

volume

10

1 reference

23 August 2017

issue

11

1 reference

23 August 2017

page(s)

1637-1658

1 reference

Epidemiology of bipolar disorders

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

The long-term natural history of the weekly symptomatic status of bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Clinical course of children and adolescents with bipolar spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Extending indications for long-term pharmacotherapy: opportunities and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

The McLean-Harvard First-Episode Mania Study: Prediction of Recovery and First Recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Recovery and functional outcomes following olanzapine treatment for bipolar I mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Treatment non-adherence in affective disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Correlation between drug treatment adherence and lithium treatment attitudes and knowledge by bipolar patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Risk of Recurrence Following Discontinuation of Lithium Treatment in Bipolar Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Using drug claims data to assess the relationship of medication adherence with hospitalization and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Bipolar disorder: from genes to behavior pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Medication use patterns and 2-year outcome in first-admission bipolar disorder with psychotic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Antidepressants in bipolar disorder: the case for caution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Effectiveness of adjunctive antidepressant treatment for bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Long-term remission and recovery in bipolar disorder: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Pharmacological Treatment Patterns at Study Entry for the First 500 STEP-BD Participants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Double-blind comparative clinical trial of pimozide and chlorpromazine in mania. A test of the dopamine hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Quetiapine or haloperidol as monotherapy for bipolar mania--a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Flupenthixol decanoate in recurrent manic-depressive illness. A comparison with lithium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Depot antipsychotic medications in bipolar disorder: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Adverse effects of antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

A meta-analysis of the efficacy of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Tolerability of atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Long-acting injectable risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Antipsychotic Drugs: Direct Correlation Between Clinical Potency and Presynaptic Action on Dopamine Neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Do we still believe in the dopamine hypothesis? New data bring new evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

The effect of aging on the pharmacokinetics and pharmacodynamics of prazosin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Meta-analysis of the impact of 9 medication classes on falls in elderly persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Incidence and predictors of drug-induced parkinsonism in older psychiatric patients treated with very low doses of neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Quantitative rating of manic states. Correlation between clinical assessment and Biegel's Objective Rating Scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

A rating scale for mania: reliability, validity and sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Risperidone long-acting injectable for maintenance therapy in bipolar disorder: An open-label pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

The concurrent validity of the Global Assessment of Functioning (GAF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Depot risperidone in the outpatient management of bipolar disorder: a 2-year study of 10 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

EuroQol--a new facility for the measurement of health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Lithium carbonate and weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Bodyweight gain and anticonvulsants: a comparative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Comparative risk for harms of second-generation antidepressants : a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

A rating scale for drug-induced akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

The InterSePT scale for suicidal thinking reliability and validity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Enhancing medication adherence in patients with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Mood state at study entry as predictor of the polarity of relapse in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Bipolar II disorder : epidemiology, diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

The effect of alcohol and substance abuse on the course of bipolar affective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Clinical features, response to treatment and functional outcome of bipolar disorder patients with and without co-occurring substance use disorder: 1-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Suicide risk in bipolar patients: the role of co-morbid substance use disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Impact of persistent substance misuse on 1-year outcome in first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Treatment adherence with antipsychotic medications in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Rapid-cycling bipolar disorder: cross-national community study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Mania and mortality: why the excess cardiovascular risk in bipolar disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Differential features between bipolar I and bipolar II disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Psychiatrists' attitudes to maintenance medication for patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

Effect of Adjunctive Lamotrigine Treatment on the Plasma Concentrations of Clozapine, Risperidone and Olanzapine in Patients With Schizophrenia or Bipolar Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.143

21 January 2018

Identifiers

DOI

10.1586/ERN.10.143

1 reference

23 August 2017

1 reference